Renewal-NAD+: A Study of Oral NAD+ and Its Multi-omic Impact in a Healthy Cohort
Renewal-NAD+: A Study of Oral NAD+ and Its Multi-omic Impact in a Healthy Cohort
NCT ID: NCT07336836 Phase: EARLY_PHASE1 Status: COMPLETED Enrollment: 60 Completion: 2022-06-04
Conditions
Health Adult Subjects, Healthy Participants
Interventions
LathMized TM NAD+ (LNAD+), Control (placebo)
Summary
The goal of this 5 day interventional study was to investigate the effects on multiple biological molecules (multi-omics) of Bryleos's commercially available oral LathMized™ Nicotinamide adenine dinucleotide (LNAD+) supplement in healthy adults aged 45-75 years. The main question to be answered was whether LNAD+ supplementation is associated with change in biological markers relevant to subjects' health. Also, the study determined whether this oral NAD+ formulation raised NAD+ levels including inside blood cells, after the 5 day treatment period, measured on post-treatment Day 1 (Day 6). Thus, the study compared NAD+ levels and impact on biological markers in the LNAD+ arm versus control placebo arm. Safety in this population was assessed using clinical laboratory tests, daily self-reporting of symptoms, and data from a wearable device.
Primary Outcome
Pharmacokinetics-NAD+ concentrations